Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

43.39 +1.34 (+3.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Via Benzinga
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Patience often pays off in the equity markets. 
Via The Motley Fool
Moderna to Present at Upcoming Conferences in May/June 2024
Via ACCESSWIRE
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
This team-up is more than a PR stunt, but it might not be revolutionary. 
Via The Motley Fool
The 10 Worst Performing S&P 500 Stocks in 2023 - Are They Good Investments Now?
A look at the 10 worst-performing S&P 500 stocks in 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
Exposures Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says. 
Via Investor's Business Daily
Exposures Product Safety
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
Moderna Announces Update on Investigational RSV Vaccine
Via ACCESSWIRE
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
Check Out What Whales Are Doing With MRNA
Via Benzinga
Moderna's Options Frenzy: What You Need to Know
Via Benzinga
Navigating 6 Analyst Ratings For Moderna
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight. 
Via The Motley Fool
Exposures COVID-19
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
Which Large-Cap Stocks Are Winning This Earnings Season? 15 Stocks To Watch (April 28-May 4, 2024)
Last week's top performers included Carvana, Pinterest, Moderna and JD.Com. 
Via Benzinga
MSFT Analysis: Why Microsoft Stock Is a Must-Own for Investors in 2024
Microsoft's cloud unit growing very rapidly and gaining market share. Coupled with a visionary CEO, Microsoft stock is a buy. 
Via InvestorPlace
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
Why Moderna Stock Blasted 13% Higher Today
The company notched beats on both the top and bottom lines despite a major drop-off in demand for its famous product. 
Via The Motley Fool
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains. 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
Via Benzinga
Exposures COVID-19
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.